Navigating a "No" When You're Seeking a GLP-1

What GLP-1 Medications Are:
GLP-1 medications (brand names such as Wegovy, Zepbound, Mounjaro, Ozempic) are prescription drugs that mimic a natural gut hormone to regulate blood sugar, reduce appetite, and slow stomach emptying, helping many people manage diabetes and weight when used properly.  

If you’re a woman over 50 thinking about a GLP-1 medication for weight management (or even for prevention, though this is off-label at this time) and your doctor won’t prescribe it, you’re not alone. And before we turn this into a story about “a doctor who doesn’t get it,” it helps to know there are a few very real reasons clinicians say no. Some are appropriate. Some are fixable. Here is the calm, practical roadmap for requesting GLP-1 medication:  

Why a doctor might say no (and what it usually means)

1. You don’t meet FDA-labeled criteria (or they think you don’t).
   For chronic weight management, both trizepatide (Zepbound) and semaglutide 2.4 mg (Wegovy) are indicated for adults with a BMI ≥30 or a BMI ≥27 with at least one weight-related condition (such as hypertension, dyslipidemia, type 2 diabetes, sleep apnea, or cardiovascular disease).  Off-label use for women who have gained 10-20 lbs during menopause, or for people at a normal body weight who want it for the brain/heart/kidney protective effects, is a much harder situation.
   
2. They’re worried about your safety or contraindications.
   These medications have known risks and boxed warnings, and some clinicians are appropriately cautious. I was too, before speaking with Dr. Anne Peters (the world-renowned LA endocrinologist who has been prescribing these medications for 20 years and told me she has NEVER seen a case of thyroid cancer associated with GLP-1’s and that that risk was found only in lab rats. ) For example, if you have a family history of medullary thyroid carcinoma or MEN2, those would be a hard stop for this drug class.
   
3. They don’t have the time or the workflow for follow-up.
   GLP-1s are not a “hand someone a prescription and wave” medicine. They require titration, management of side effects, and ongoing monitoring. Some doctors just simply don’t have the time to commit to proper patient management with this drug. It’s a good thing if your doc knows their limits.  
    
4. They aren’t current or comfortable.
   Some clinicians simply haven’t incorporated obesity medicine into routine practice yet. That’s not a moral failure. It’s a systems issue, and I respect it.

Tackling barriers to weight-related medications is often more about communication, documentation, insurance, and logistics than it is about your body. Here’s a practical step-by-step approach that empowers you without guesswork.  

1.) Politely ask for the reason for “no” in writing

Don’t allow a vague “I don’t prescribe that” to be the end of the conversation. Ask your clinician to email or note in your record the specific barrier: eligibility criteria, safety concerns, experience, insurance, etc.  

Why it matters: Clear documentation enables you and your care team to address the real issue, rather than relying on assumptions.

2.) Bring a one-page safety snapshot to your visit

Make it easy for your clinician to assess appropriateness by providing them with the necessary clinical context to quickly evaluate eligibility and safety.  

Include:

• Your current weight, height, and BMI. (Calculate your BMI here.)
• Weight-related diagnoses (Blood pressure, prediabetes, type 2 diabetes, lipids, sleep apnea, fatty liver disease, cardiovascular history)
• Prior weight-loss attempts (your lifestyle, nutrition, medications, structured interventions)
• Relevant medical history (pancreatitis, gallbladder disease, severe GI motility disorders, personal or family history of medullary thyroid cancer or MEN2, pregnancy, or plans for pregnancy)  

Why it works: GLP-1 medications are indicated for adults with a BMI ≥30, or a BMI ≥27 with at least one weight-related condition. Summarizing this upfront helps your doc apply guidelines efficiently.  

3.) Clinician consideration

Studies show that clinician comfort and training strongly influence whether evidence-based obesity treatments are offered. Some clinicians are uncomfortable managing obesity pharmacotherapy, particularly dose titration, side effects, and long-term maintenance. If these are the issues, switch the clinician, not the goal.

What to look for:

• Providers with Obesity Medicine training (check ABOM.org to find one near you)
• Endocrinologists or cardiometabolic specialists
• Primary care clinicians who focus on obesity care

Why this matters: Provider comfort with dose titration, side-effect management, and long-term follow-up improves care quality and outcomes.

4.) Treat insurance like a benefits problem

Coverage for anti-obesity medications varies widely across plans and often requires prior authorization with documentation of your medical history and comorbidities. This is important because denials are often overturned on appeal when prior attempts are clearly documented.

Why it matters: Insurance decisions are documentation-driven, not based on personal preference.  

Practical steps:

• Ask if the office routinely submits prior authorizations.  
• If denied, appeal using documented comorbidities and previous weight-loss efforts.  
• If you have established cardiovascular disease and meet criteria, note that semaglutide has evidence for cardiovascular risk reduction in people with overweight/obesity without diabetes.
• Consider paying out of pocket (OOP); the prices for these meds have come way down recently. While not cheap, paying OOP could save you money long-term by improving your overall health.

5.) Understand “off-label” use

An off-label use means prescribing an FDA-approved medication for something not listed on the official label.  

Examples:

• Using Ozempic (semaglutide) for weight loss is off-label
• Zepbound is the FDA-approved version specifically labeled for obesity

Why this matters: Off-label prescribing can be appropriate, but it may affect insurance coverage and requires careful follow-up and monitoring.

6.) Be cautious with compounded or “unapproved GLP-1” products

The FDA has raised specific concerns about unapproved GLP-1 drugs, including the use of unapproved salt forms (semaglutide sodium/acetate), and reports of dosing errors and adverse effects, including hospitalization, linked to compounded semaglutide.  

While I understand that cost and access concerns drive people toward compound products, it's crucial to understand that safety issues are real.  

Why this matters: Since compounded products may vary in quality, potency, and dosing, they are not interchangeable with FDA-approved medications. Discuss risks and benefits with your clinician if considering any non-approved option.

What Good Follow-Up Actually Looks Like (Non-Negotiable)

Starting a GLP-1 is not a DIY situation. Obesity and the condition of being overweight are chronic conditions. Stopping medication without a plan often leads to weight regain. High-quality care includes an ongoing plan, clear guardrails, and proactive monitoring and/or maintenance.

At a minimum, a good follow-up should include:

• A clear dose-escalation plan
  
• Defined nutrition targets, especially protein
  
• Monitoring for known risks
  
• A long-term maintenance strategy
  
  

Bottom line

You deserve an evidence-based care plan that is clearly documented and tailored to your health goals. If your doctor won’t prescribe a GLP-1, don’t default to panic or to sketchy workarounds. Instead, get clarity on why, document eligibility, and, if needed, transfer your care to someone trained and current in obesity medicine. That’s the safest, highest-return path for women over 50 who want results without chaos.

‍